REMS – Page 3 – Policy & Medicine

New Hampshire Legislation Targets Boards that Govern Opioid Prescribers

Update on Risk Evaluation and Mitigation Strategies

FDA REMS Open Public Meeting Explored Need for Flexibility in REMS Programs

FDA REMS: FDA Hosting a Two Day Meeting on Issues and Challenges with REMS Standardization and Assessment

FDA MedWatch Safety and Adverse Event Reporting Program Expands Patient Resources

CME Programs to Reduce Opioid Abuse

ER-LA Opioid REMS CME Critics and the ACCME’s Vigorous Response

FDA REMS: Mycophenolate Class Wide REMS

The Joint Commission Provides Hospitals Guidance for Better Opioid Use Management

FDA Releases Final Risk Evaluation and Mitigation Strategies (REMS) for Extended Release/Long Acting Opioids Including a Prescriber Education Program